Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia

Abstract

Sorafenib is a multi-kinase inhibitor with activity against several intracellular kinases which may play a role in the pathogenesis of acute myeloid leukemia (AML). In vitro data and results from early clinical trials suggest that sorafenib might be an effective drug for the treatment of AML. However, clinical data are still sparse, and there are only a few reported cases of monotherapy. The aim of the present research was to collect clinical data on efficacy and safety in a systematic way by conducting a survey on clinical experience with sorafenib. Thirty institutions were asked to document all patients treated with sorafenib diagnosed with AML. Of all 29 evaluable patients, six (21%) responded to sorafenib containing treatment by achieving a complete remission (CR, n = 2) or complete remission with incomplete platelet recovery (CRi, n = 4). In 23 patients receiving sorafenib as monotherapy, the CRi rate amounted to 13% and no CRs were documented. Of the 18 FLT-ITD positive patients with sorafenib monotherapy, two patients achieved a CRi (11%). In five FLT3-ITD negative cases, one CRi was documented (20%). Our results suggest the potential ability of the drug to induce remissions in refractory or relapsed AML even when given as monotherapy.

Keywords::

• Myeloid leukemias and dysplasias
• signaling therapies
• signal transduction

Potential conflict of interest

Two of the authors (H.S. and G.E.) conducted clinical trials with sorafenib which were supported by the manufacturer of sorafenib, Bayer Healthcare Germany. Disclosure forms provided by the authors are available with the full text of this article at http://www.informahealthcare.com/lal.